Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)

On March 4, Guggenheim accrued the terms people connected Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $200 from $100. The steadfast maintains its Buy standing connected the banal with an upside imaginable of astir 207%.

The accommodation follows updates to the firm’s model, which raised its estimates for claseprubart. Guggenheim present projects astir $2.8 cardinal successful planetary highest income from CIDP patients and estimates astir $2 cardinal successful planetary income from the gMG indication.

On January 29, Oppenheimer accrued its terms people connected Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $125 from $62 portion maintaining an Outperform rating. The steadfast points retired that Dianthus shares person gained 22% twelvemonth to date, compared with XBI’s 5% rise. This is chiefly owed to the comments from CEO Marino Garcia during the January healthcare league connected the imaginable superiority of the company’s merchandise implicit the competitor’s complement inhibitors.

Dianthus Therapeutics Inc. (NASDAQ:DNTH) is simply a clinical-stage biotechnology institution dedicated to transforming the attraction of terrible autoimmune and inflammatory diseases. They specialize successful engineering highly selective monoclonal antibodies, specified arsenic their pb campaigner claseprubart, to amended upon existing complement therapies. Their absorption is connected delivering potent, patient-friendly, and convenient attraction options.

While we admit the imaginable of DNTH arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest successful According to Hedge Funds.

Disclosure: None. Follow Insider Monkey connected Google News.